NasdaqCM - Delayed Quote USD

OmniAb, Inc. (OABIW)

Compare
0.3300 0.0000 (0.00%)
At close: October 21 at 4:00 PM EDT
Loading Chart for OABIW
DELL
  • Previous Close 0.3300
  • Open 0.3300
  • Bid --
  • Ask --
  • Day's Range 0.3300 - 0.3300
  • 52 Week Range 0.3300 - 0.3300
  • Volume 24,952
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

www.omniab.com

106

Full Time Employees

--

Fiscal Year Ends

Recent News: OABIW

View More

Compare To: OABIW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OABIW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -287.29%

  • Return on Assets (ttm)

    -13.95%

  • Return on Equity (ttm)

    -19.87%

  • Revenue (ttm)

    21.71M

  • Net Income Avi to Common (ttm)

    -62.38M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    57.23M

  • Total Debt/Equity (mrq)

    8.27%

  • Levered Free Cash Flow (ttm)

    -17.42M

Company Insights: OABIW

People Also Watch